DE10311984A8 - Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten - Google Patents
Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten Download PDFInfo
- Publication number
- DE10311984A8 DE10311984A8 DE10311984A DE10311984A DE10311984A8 DE 10311984 A8 DE10311984 A8 DE 10311984A8 DE 10311984 A DE10311984 A DE 10311984A DE 10311984 A DE10311984 A DE 10311984A DE 10311984 A8 DE10311984 A8 DE 10311984A8
- Authority
- DE
- Germany
- Prior art keywords
- nonimmunogenic
- nep
- hypertensive
- treatment
- associated molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010020772 Hypertension Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001631 hypertensive effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Alternative & Traditional Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10311984A DE10311984A1 (de) | 2003-03-12 | 2003-03-12 | Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten |
EP04718256A EP1608355A2 (de) | 2003-03-12 | 2004-03-08 | Verwendung von nep-assoziierten molek len zur behandlung von nichtimmunogenen-nichthypertensiven zivilisationskrankheiten |
PCT/DE2004/000491 WO2004080448A2 (de) | 2003-03-12 | 2004-03-08 | Verwendung von nep-assoziierten molekülen zur behandlung von nichtimmunogenen-nichthypertensiven zivilisationskrankheiten |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10311984A DE10311984A1 (de) | 2003-03-12 | 2003-03-12 | Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten |
Publications (2)
Publication Number | Publication Date |
---|---|
DE10311984A1 DE10311984A1 (de) | 2004-09-23 |
DE10311984A8 true DE10311984A8 (de) | 2005-01-27 |
Family
ID=32892302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10311984A Ceased DE10311984A1 (de) | 2003-03-12 | 2003-03-12 | Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1608355A2 (de) |
DE (1) | DE10311984A1 (de) |
WO (1) | WO2004080448A2 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102499179A (zh) * | 2011-11-24 | 2012-06-20 | 上海市普陀区中心医院 | 一种IgAN肾小球硬化大鼠模型的建立方法 |
WO2018119178A1 (en) * | 2016-12-23 | 2018-06-28 | StemBios Technologies, Inc. | Use of somatic stem cells for decreasing neprilysin level |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200426A (en) * | 1990-08-14 | 1993-04-06 | Board Of Regents, The University Of Texas | Inhibitors of neutral endopeptidase/CALLA as chemotherapeutic agents |
JPH04112865A (ja) * | 1990-09-03 | 1992-04-14 | Dainippon Pharmaceut Co Ltd | 置換アミド誘導体 |
DE4212250A1 (de) * | 1992-04-11 | 1993-10-14 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE69300826T2 (de) * | 1993-09-22 | 1996-04-18 | Pfizer Research And Development Co., N.V./S.A., Dublin | Hydrierung. |
CH690816A5 (de) * | 1996-10-24 | 2001-01-31 | Flachsmann Ag Emil | Verwendung eines Teil- oder Vollextrates aus nicht fermentierter Camellia sinensis L. zur Herstellung eines Medikamentes, eines Medizinproduktes, eines kosmetischen Präparates oder eines Nahrungsergänzungsproduktes. |
EP0977572A1 (de) * | 1997-04-24 | 2000-02-09 | Merck Sharp & Dohme Ltd. | Verwendung von nk-1 rezeptor-antagonisten zur behandlung von essstörungen |
CN1267463A (zh) * | 1998-06-08 | 2000-09-27 | 扬州四菱食品有限公司 | 减肥茶及其制作方法 |
TR200103332T2 (tr) * | 1999-05-21 | 2002-04-22 | Pfizer Products Inc. | 1-Triflorometil-4-hidroksi-7-piperidinil-aminometilkroman türevleri. |
TWI302149B (en) * | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
GB2369118A (en) * | 2000-11-17 | 2002-05-22 | Warner Lambert Co | Bombesin receptor antagonists |
GB0111709D0 (en) * | 2001-05-14 | 2001-07-04 | Pfizer Ltd | Novel pharmaceuticals |
WO2003059289A2 (en) * | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
DE10224844A1 (de) * | 2002-06-05 | 2004-01-08 | Solvay Pharmaceuticals Gmbh | Nicht-peptidische BRS-3-Agonisten |
-
2003
- 2003-03-12 DE DE10311984A patent/DE10311984A1/de not_active Ceased
-
2004
- 2004-03-08 WO PCT/DE2004/000491 patent/WO2004080448A2/de active Application Filing
- 2004-03-08 EP EP04718256A patent/EP1608355A2/de not_active Ceased
Non-Patent Citations (10)
Title |
---|
AN 2003:766618 zu: Obese phenotype in NEP knockout mice: Correlation with age and diet and possible molecular mechanism. Becker, M. u.a., NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, (MAR 2003) Vol. 367, Supp. [1], pp. R6-R6. MA 11 [rech. am 17.11.2003] * |
CYNSHI, O. u.a.: Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proc. Natl. Acad. Sci. USA (1998) 95 (17) 10123-10128 * |
Datenbank PubMed bei NCBI, Adresse www.ncbi.nlm. * |
Datenbank PubMed bei NCBI, Adresse www.ncbi.nlm. nih.gov, Zusammenfassung zu: VALET, P. u.a.: Understanding adipose tissue development from transgenic animal models. J. Lipid Res. (2002) 43 (6) 835-60 [rech. am 18.11.2003] |
Datenbank PubMed bei NCBI, Adresse www.ncbi.nlm. nih.gov, Zusammenfassung zu: VALET, P. u.a.: Understanding adipose tissue development from transgenic animal models. J. Lipid Res. (2002) 43 (6) 835-60 [rech. am 18.11.2003] * |
Datenbank SCISEARCH bei STN * |
Datenbank SCISEARCH bei STN; AN 2003:766618 zu: Obese phenotype in NEP knockout mice: Correlation with age and diet and possible molecular mechanism. Becker, M. u.a., NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, (MAR 2003) Vol. 367, Supp. [1], pp. R6-R6. MA 11 [rech. am 17.11.2003] |
IEMS, W.-E. u.a.: Neutral endopeptidase and alcohol consumption, experiments in neutral endopeptidase-deficient mice. Eur. J. Pharmacol. (2000) 397 (2-3) 327-34 * |
nih.gov, Zusammenfassung zu: ARBIN, V. u.a.: Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat. Br. J. Pharmacol. (2001) 133 (4) 495-502 [rech. am 18.11.2003];$ |
SIEMS, W.-E. u.a.: Neutral endopeptidase and alcohol consumption, experiments in neutral endopeptidase-deficient mice. Eur. J. Pharmacol. (2000) 397 (2-3) 327-34 |
Also Published As
Publication number | Publication date |
---|---|
DE10311984A1 (de) | 2004-09-23 |
WO2004080448A2 (de) | 2004-09-23 |
WO2004080448A3 (de) | 2004-12-16 |
EP1608355A2 (de) | 2005-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004022061D1 (de) | Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen | |
ATE518841T1 (de) | Herstellung und verwendung von arylalkylsäurederivaten zur behandlung von obesitas | |
ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
ATE494279T1 (de) | Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate | |
DE602004028763D1 (de) | Te zur behandlung von virenerkrankungen | |
ATE440866T1 (de) | Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten | |
DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
ATE524479T1 (de) | Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren | |
ATE447551T1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
DE60320007D1 (de) | Phenethanolamin-derivate zur behandlung von atemwegserkrankungen | |
ATE512663T1 (de) | Kombination zur behandlung von erkrankungen mit zellproliferation | |
ATE369133T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
ATE369333T1 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
DE50306850D1 (de) | Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen | |
ATE375977T1 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
DE502005010499D1 (de) | Implantat zur Behandlung von Fettsucht | |
DE60328517D1 (de) | Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung | |
ATE443704T1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
DE602006007323D1 (de) | VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN | |
DE602005016141D1 (de) | S-mirtazapin zur behandlung von hitzewallungen | |
DE602004022035D1 (de) | Verwendung von pthalide derivativen zur behandlung | |
ATE423099T1 (de) | Zur behandlung von schmerzen geeignete piperazine | |
ATE482707T1 (de) | 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen | |
DE602005015434D1 (de) | Mittel zur behandlung von psychoneurotischen krankheiten | |
ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8196 | Reprint of faulty title page (publication) german patentblatt: part 1a6 | ||
OP8 | Request for examination as to paragraph 44 patent law | ||
8181 | Inventor (new situation) |
Inventor name: MELZIG, MATTHIAS F., DR., 12623 BERLIN, DE Inventor name: SIEMS, WOLF E., DR., 12683 BERLIN, DE Inventor name: WALTHER, THOMAS, PROF., 12203 BERLIN, DE |
|
8131 | Rejection |